On January 16, 2026, Jeremy B. Hayden, serving as Chief Legal Officer for Sight Sciences, Inc. (NASDAQ: SGHT), executed the sale of 6,308 shares of the company's common stock. This transaction, documented in a Form 4 filing with the Securities and Exchange Commission, detailed multiple trades made at prices spanning from $6.44 to $6.69 per share, reflecting a weighted average price of $6.62. The aggregate proceeds of these sales totaled approximately $41,758.
Following these sales, Hayden retains direct ownership of 267,611 shares of Sight Sciences stock, which encompass 75,562 shares of common stock and an additional 192,049 shares structured as restricted stock units slated for acquisition upon vesting.
At present, SGHT shares are trading at $6.38 amid a relatively high beta of 2.41, indicating notable price volatility. Analysis from InvestingPro suggests the stock may be overvalued relative to its calculated Fair Value, signaling potential market premium.
Sight Sciences currently holds a market capitalization of approximately $336.79 million. While the company has not posted profitability within the preceding twelve months, it has delivered a strong total return of 121.53% over the past year. Financially, the firm maintains a solid liquidity position, boasting a current ratio of 9.6, and has a cash balance exceeding its total debt obligations.
In an outlook provided during this period, Sight Sciences announced preliminary revenue guidance for the fourth quarter of 2025 in the range of $20.3 million to $20.4 million. This guidance equates to an approximate 7% increase compared to the corresponding quarter in the previous year. Breaking down revenue streams, the Surgical Glaucoma division is forecasted to produce between $19.6 million and $19.7 million, marking a 5% year-over-year rise, while the Dry Eye segment is projected at roughly $0.7 million, which represents significant growth around 130% from Q4 2024.
Investor sentiment has shown signs of optimism. Piper Sandler recently upgraded its rating on Sight Sciences stock from Neutral to Overweight. This adjustment was influenced by positive expectations for the company's TearCare product opportunity, although the firm advises a degree of caution as the company works towards achieving payor coverage. Complementary clinical developments include favorable study outcomes for the OMNI device, demonstrating sustained reductions in intraocular pressure and decreased medication dependency among glaucoma patients.
Further institutional analyst activity includes Needham's maintenance of a Hold rating following the company exceeding revenue expectations in its third-quarter 2025 results, which prompted management to raise full-year revenue forecasts.
The company has recently undergone leadership changes to strengthen its executive team. Effective November 5, 2025, Alison Bauerlein assumed the role of Chief Operating Officer, and James Rodberg was appointed as Chief Financial Officer. Bauerlein brings experience as former CFO of Inogen, where she played a prominent role in expanding annual sales beyond $350 million.